• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多站纵隔淋巴结受累的非小细胞肺癌诱导治疗

Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations.

作者信息

Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H

机构信息

Department of Thoracic Surgery, Hyogo Medical Center for Adults, Akashi City, Hyogo Japan.

出版信息

Chest. 2000 Jul;118(1):123-8. doi: 10.1378/chest.118.1.123.

DOI:10.1378/chest.118.1.123
PMID:10893369
Abstract

BACKGROUND

Metastasis to multiple stations of mediastinal nodes is associated with a poor prognosis.

OBJECTIVE

: We prospectively examined the efficacy of induction therapy plus surgery in patients with non-small cell lung cancer and metastases at multiple stations of mediastinal (N2) lymph nodes.

METHODS

Among the 1,085 patients who underwent surgery for primary non-small cell lung carcinoma from 1985 to 1997, those with clinical N2 disease of involved multiple stations, defined as bulky, mediastinal, lymph node metastases on CT scans, received induction therapy, consisting of cisplatin-based chemotherapy and radiation of 40 Gy.

RESULTS

Of the 88 eligible patients entered into the study, 51 (58%) had multiple stations of N2 nodes affected preoperatively, as demonstrated by pathologic examination. Neither operative mortality nor fatal, treatment-related complications occurred during hospitalization. Patients who underwent complete resection had significantly longer survivals than did those who underwent incomplete resection (p = 0. 001). Among patients who underwent complete resection, the survival rate for patients with pathologically downstaged disease was significantly higher than that for patients whose disease was not downstaged (p = 0.009). Among patients with multiple stations of pN2 nodes involved who had undergone complete resection, those who received induction therapy for bulky N2 disease had a significantly better prognosis than did those undergoing surgery alone for nonbulky N2 disease (p = 0.03).

CONCLUSIONS

Induction therapy prolonged the survival of patients with non-small cell lung cancer and mediastinal nodes involved at multiple stations. Survival was better when complete resection and downstaging of the disease were achieved after induction therapy.

摘要

背景

纵隔淋巴结多站转移与预后不良相关。

目的

我们前瞻性地研究了诱导治疗加手术对非小细胞肺癌合并纵隔(N2)淋巴结多站转移患者的疗效。

方法

在1985年至1997年接受原发性非小细胞肺癌手术的1085例患者中,那些临床诊断为N2期且累及多站的患者,即CT扫描显示为巨大纵隔淋巴结转移者,接受诱导治疗,包括以顺铂为基础的化疗和40 Gy的放疗。

结果

纳入研究的88例合格患者中,病理检查显示51例(58%)术前有多站N2淋巴结受累。住院期间未发生手术死亡或致命的、与治疗相关的并发症。接受根治性切除的患者生存期明显长于未完全切除的患者(p = 0.001)。在接受根治性切除的患者中,病理分期降低的患者生存率明显高于分期未降低的患者(p = 0.009)。在多站pN2淋巴结受累且接受根治性切除的患者中,因巨大N2疾病接受诱导治疗的患者预后明显好于仅因非巨大N2疾病接受手术的患者(p = 0.03)。

结论

诱导治疗延长了非小细胞肺癌合并纵隔多站淋巴结受累患者的生存期。诱导治疗后实现疾病的根治性切除和分期降低时,生存期更佳。

相似文献

1
Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations.多站纵隔淋巴结受累的非小细胞肺癌诱导治疗
Chest. 2000 Jul;118(1):123-8. doi: 10.1378/chest.118.1.123.
2
Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.非小细胞肺癌病理ⅢA期(N2)三联疗法后的疾病失败模式。癌症与白血病B组方案8935分析。
Cancer. 1996 Jun 1;77(11):2393-9. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2393::AID-CNCR31>3.0.CO;2-Q.
3
The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.诱导治疗后残留多水平N2期疾病对非小细胞肺癌的影响。
Lung Cancer. 2003 Oct;42(1):69-77. doi: 10.1016/s0169-5002(03)00245-9.
4
[Surgical treatment of non-small cell lung cancer with mediastinal node invasion. A retrospective study].[纵隔淋巴结转移非小细胞肺癌的外科治疗:一项回顾性研究]
Arch Bronconeumol. 2001 Mar;37(3):121-6. doi: 10.1016/s0300-2896(01)75033-8.
5
Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.基线可切除 IIIA-N2 期非小细胞肺癌的外科多模态治疗。纵隔淋巴结受累程度及对生存的影响。
Eur J Cardiothorac Surg. 2009 Sep;36(3):433-9. doi: 10.1016/j.ejcts.2009.04.013. Epub 2009 Jun 6.
6
The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement.手术辅助胸部放射治疗对同侧纵隔淋巴结受累的非小细胞肺癌患者的影响。
Cancer. 1997 Oct 15;80(8):1399-408. doi: 10.1002/(sici)1097-0142(19971015)80:8<1399::aid-cncr6>3.0.co;2-a.
7
Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.接受诱导化疗后接受手术的pN2“潜在可切除”非小细胞肺癌患者的预后
Semin Thorac Cardiovasc Surg. 2016;28(2):593-602. doi: 10.1053/j.semtcvs.2015.12.001. Epub 2015 Dec 10.
8
Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.肺癌中N1和N2站之间的边界:下叶肿瘤淋巴结转移模式的经验教训
J Thorac Cardiovasc Surg. 2005 Apr;129(4):825-30. doi: 10.1016/j.jtcvs.2004.06.016.
9
Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).非小细胞肺癌伴纵隔淋巴结转移(N2)的外科治疗策略
Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):342-8. doi: 10.3779/j.issn.1009-3419.2010.04.14.
10
Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved.是时候优化 N2 分期了?基于局部区域受累情况的 cN2α 和 cN2β 相比单独的 N2 或受累淋巴结站数量,能为接受手术治疗的 IIIA 期非小细胞肺癌提供更准确的预后评估。
Eur J Cardiothorac Surg. 2014 Jul;46(1):86-91. doi: 10.1093/ejcts/ezt550. Epub 2013 Dec 8.

引用本文的文献

1
Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).诱导性 PD-1 抑制剂特瑞普利单抗联合化疗,随后行同期放化疗和巩固性特瑞普利单抗治疗局部晚期非小细胞肺癌的容积肿瘤患者:一项随机 II 期试验方案(InTRist 研究)。
Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. eCollection 2023.
2
Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer.IIIA/N2期非小细胞肺癌三联疗法中与治疗相关的预测和预后因素
Front Oncol. 2018 Feb 20;8:30. doi: 10.3389/fonc.2018.00030. eCollection 2018.
3
Pneumonectomy for node-positive non-small cell lung cancer: can it be a treatment option for N2 disease?针对淋巴结阳性非小细胞肺癌的肺切除术:它能否成为N2期疾病的一种治疗选择?
Gen Thorac Cardiovasc Surg. 2014 Jun;62(6):370-5. doi: 10.1007/s11748-014-0380-3. Epub 2014 Mar 1.
4
Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients.新辅助治疗后手术治疗 IIIA 期 N2 非小细胞肺癌患者的预后因素和长期结果。
Ann Thorac Med. 2009 Oct;4(4):201-7. doi: 10.4103/1817-1737.56010.
5
Prognostic significance of persistent mediastinal metastasis following induction therapy in large (> or = 2 cm) N2 or N3 non-small cell lung cancer.
Jpn J Thorac Cardiovasc Surg. 2003 Apr;51(4):123-9. doi: 10.1007/s11748-003-0047-y.